ZYBERNO
Stock Report
Updated Aug 31, 2026

Rapid Micro Biosystems, Inc. (RPID)

NASDAQ

$1.53

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
21.0/100
POOR BUSINESS
Rapid Micro Biosystems, Inc. (RPID) scores 21/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-177.0%)
Debt-to-Equity (Solvency Risk):GOOD (0.48x)
Operating Margin (Operational Efficiency):CRITICAL (-141.5%)
Return on Capital (Capital Efficiency):CRITICAL (-158.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Rapid Micro Biosystems, Inc. (RPID) stock report — Zyberno Score 21/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RPID generated -$37.98M in Owner Earnings. Capital was deployed as follows: $925.00K invested in capital expenditures. Reinvestment rate: 6.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.53
Market Cap:$73.97M

Valuation Multiples (3)

P/B Ratio:4.17x
P/S Ratio:2.10x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$79.71M

Price Action & Momentum (3)

Momentum Percentile:8 / 100
% of 52-Week High:31.0%
B. Profitability Assessment

Return Metrics (5)

ROA:-73.1%
Reinvestment Rate:6.4%
Fundamental Growth Rate (g):-10.2%

Margin Analysis (3)

Operating Margin Ttm:-141.5%
Net Margin Ttm:-145.6%
Ebitda Margin:-132.6%

TTM Performance (2)

Operating Margin Ttm:-141.5%
Net Margin Ttm:-145.6%

Yield Metrics (2)

Earnings Yield:-$64.71
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-124.8%
Latest Earnings Filed:2026-08-07

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):20.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.55x
Quick Ratio:1.51x
Cash Ratio:0.81x

Leverage Analysis (3)

Debt To Equity Ttm:0.48x
Debt-to-Equity Ratio:0.48x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-73.36x
Times Interest Earned:-73.36

Capital Structure (4)

Working Capital:28,112,000.00
Cash And Cash Equivalents:14,687,000.00
Long Term Debt:$19.14M
Net Debt:$5.74M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $35.18M
Linear Growth: 20.6%
📊 Click to view full RPID Revenue analysis & methodology →
Cost Of Revenue Ttm:$27.37M

Profitability Breakdown (2)

$113.34M-$49.76M

Bottom Line Performance (3)

-$51.20M
Income Before Tax:-$65.39M
Ebitda Ttm:-46,646,000.00

Operating Expenses (5)

Operating Expenses:70,460,000.00
R And D Expense:13,440,000.00
Sga Expense:25,193,000.00
Income Tax Expense:$75.00K
Interest Expense:646,000.00

Expense Ratios (3)

R And D To Revenue Percentage:166.9%
Sga To Revenue Percentage:312.8%
Ebitda Margin:-132.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$58.45M
Current Assets:$46.26M
Ppe Net:28,779,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:40,702,000.00
Current Liabilities:18,150,000.00
Long Term Debt:$19.14M
Short Term Debt:$1.29M

Equity & Capital (3)

Equity:$17.75M
Retained Earnings:-$549.60M
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:5,515,000.00
Inventory:18,918,000.00
Accounts Payable:5,177,000.00

Special Items (2)

Contract Liabilities:5,508,000.00
Stock Based Compensation:1,321,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$37.06M-$37.98M

Investment Activities (2)

Investing Cash Flow:$8.60M
Capital Expenditures Ttm:925,000.00

Financing Activities (3)

Financing Cash Flow:$247.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:445,000.00
Long Term Debt Issuance:$20.00M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:3,111,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.10
-$1.10
Earnings Per Share Ttm:-$1.06

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.73
Operating Cash Flow Per Share:-$0.64

Book Value & Capital (2)

Book Value Per Share:$0.37
Cash Per Share:0.30

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.50x
Working Capital Turnover Ttm:1.25x

Receivables Management (2)

Receivables Turnover Ttm:6.38x
Days Sales Outstanding Ttm:57.23

Inventory Management (2)

Inventory Turnover Ttm:1.45x
Days Inventory Outstanding Ttm:252.30

Payables & Cash Cycle (2)

Days Payable Outstanding:69.04
Cash Conversion Cycle:240.49
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$37.98M

Damodaran Growth Analysis (2)

Reinvestment Rate:6.4%
Fundamental Growth Rate (g):-10.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):20.6%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-41.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:RPID
Company Name:Rapid Micro Biosystems, Inc.
Sector:Unknown
Industry:Laboratory Analytical Instruments
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:48.35M
Shares Outstanding Basic:48.35M
Shares Outstanding Diluted:48.35M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 18:56:27 UTC
Data Timestamp:2026-08-19T18:42:23.507270
Scroll to Top